The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

What Was Tested

The paper reports a study of Glucagon and Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes.

The researchers hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period.

Who Took Part

The study group was 11 subjects.

By PubMed's age tags, the people studied were teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Glucagon study: the subjects and staff both knew the treatment.

Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min.

What Was Measured

Topics PubMed links to this paper include Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Glucagon, Hyperglycemia, Hypoglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized and open-label study of Glucagon and Amylin (Islet Amyloid Polypeptide) in 11 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (Diabetes), a journal based in United States.

More context: the Glucagon compound page and the Amylin (Islet Amyloid Polypeptide) compound page.